Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
Back to event

The DEA banned a drug some opioid users called a miracle

By Manisha Krishnan, wired.com · Nov 4, 2026, 9:08 AM CST

Read full article at Ars Technica
In 2012, as the driver of deaths in the opioid crisis began moving from prescription pills to heroin, Laura Bohn was tasked with finding safer drugs to manage pain. Funded by the National Institute on Drug Abuse, in 2017 she and other scientists revealed in the science journal Cell that several compounds—including a particularly promising one called SR-17018—could relieve pain in mice without caus

Excerpt shown under fair-use limits. Full text remains with the original publisher.

People in this coverage

Explore their history and attributable record. Being mentioned does not imply endorsement.

Layer 1 · Claims & fact checks

AI analysis

Layer 2 · Biblical perspective

Biblical interpretation
INSUFFICIENT CONTEXT
Read the biblical analysis

Layer 3 · Reporting analysis

AI analysis

SensationalismThe headline frames the scientific finding as a dramatic ban, creating a sense of urgency and drama without evidence.

Appeal to HopeThe article emphasizes the potential of the compound to solve a major problem in the opioid crisis, appealing to readers' desire for a breakthrough.

Authority AppealCiting federal funding is used to lend credibility to the research.

OmissionThe article truncates before providing details on the study methodology or any discussion of limitations, leaving readers without full context.

Context

AI analysis

Missing context

The article does not provide any information about a DEA ban, including when it occurred, the legal basis, or official statements from the DEA. It also lacks context about whether SR‑17018 has been tested in humans, its regulatory status, or any subsequent research.

Important context

The findings are limited to pre‑clinical mouse studies; efficacy and safety in humans remain unproven. Funding by a federal agency (NIDA) does not imply regulatory approval. Patent filing does not equate to market availability.

Opinion vs. reporting

AI analysis

The piece mixes reporting of scientific results with a sensational headline that implies regulatory action not supported by the text, blurring the line between factual reporting and opinion.